SCHEMBL3007516

SCHEMBL3007516

CCOc1ccc(-c2csc(N3CCC(S(=O)(=O)c4cc(F)ccc4C)CC3)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.50
MAPT P10636 9/20 0.50
MAPK1 P28482 6/20 0.50
LMNA P02545 6/20 0.50
HTT P42858 2/20 0.50
RAB9A P51151 5/20 0.46
L3MBTL1 Q9Y468 4/20 0.46
NPC1 O15118 3/20 0.46
ALDH1A1 P00352 5/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NR2F2 P24468 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
AR P10275 2/20 0.42
TSHR P16473 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MCOLN3 Q8TDD5 1/20 0.42
USP2 O75604 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019395 0.90 SMN1; SMN2 (0.48) SMN1; SMN2MAPTMAPK1LMNAHTT
SCHEMBL3011213 0.90 SMN1; SMN2 (0.55) SMN1; SMN2MAPTMAPK1LMNAHTT
SCHEMBL3010502 0.89 CTSS (0.48) SMN1; SMN2MAPTMAPK1LMNAHTT
SCHEMBL3015211 0.89 MAPK1 (0.49) SMN1; SMN2MAPTMAPK1LMNAHTT
SCHEMBL3016318 0.88 SMN1; SMN2 (0.53) SMN1; SMN2MAPTMAPK1LMNAHTT
SCHEMBL3015953 0.87 MAPK1 (0.48) SMN1; SMN2MAPTMAPK1LMNAHTT
SCHEMBL3008199 0.87 MAPK1 (0.51) SMN1; SMN2MAPTMAPK1LMNAHTT
SCHEMBL2998418 0.87 SMN1; SMN2 (0.55) SMN1; SMN2MAPTMAPK1LMNAHTT
SCHEMBL3009935 0.86 MAPT (0.35) SMN1; SMN2MAPTMAPK1LMNAHTT
SCHEMBL3016492 0.86 MAPK1 (0.52) SMN1; SMN2MAPTMAPK1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885MAPT 18/4885MAPK1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.